Navigation Links
Should Cystic Fibrosis Patients Get So Many Antibiotics?
Date:3/26/2012

MONDAY, March 26 (HealthDay News) -- Antibiotics can prolong cystic fibrosis patients' lives, but the drugs also help treatment-resistant bacteria thrive in their lungs, a new, small study suggests.

The findings from the 10-year investigation suggest, but do not prove, that the current standard of aggressive antibiotic treatment for cystic fibrosis patients may not always be the best approach.

It's common to use antibiotics to control infection in cystic fibrosis patients' lungs, but maintaining a more diverse range of bacteria in the lungs may help some patients stay healthy longer, according to study senior author Dr. John LiPuma, a research professor of pediatrics and communicable diseases at the University of Michigan Medical School in Ann Arbor.

"The conventional wisdom has been that as patients with cystic fibrosis age and become sicker, as their lung disease progresses, more and more bacteria move in," he said in a university news release. "But our study -- which was the first to examine the bacterial communities in cystic fibrosis patients' lungs over a long period of time -- indicates that's not what happens."

Aggressive use of antibiotics actually lowers the diversity of lung bacteria, resulting in infections that are increasingly difficult to treat. A more diverse community of lung bacteria may help keep the most dangerous strains in check, the researchers noted.

"What we normally do is essentially carpet bombing with antibiotics," explained LiPuma. "However, what we found is that over time this ultimately helps treatment-resistant bacteria by getting rid of their competition."

He said the findings may be a first step toward developing new treatment methods, such as more focused use of antibiotics or even giving cystic fibrosis patients beneficial bacteria.

The study was published March 26 in the Proceedings of the National Academy of Sciences.

Cystic fibrosis is a chronic disease in which the body produces thick, sticky mucus that clogs the lungs. The accumulation of the mucus leaves people prone to serious, hard-to-treat and recurrent infections. Eventually, the repeated infections destroy the lungs.

In the study, researchers examined the bacteria from six patients collected over eight to nine years. Half of the patients had a relatively stable type of the disease and the others had the more typical, faster-progressing form. The investigators conducted DNA analysis on bacteria in 126 sputum samples.

Over time, the researchers found that bacterial diversity declined, yet the overall level of bacteria remained fairly constant. The study authors explained that this means a small number of organisms multiply to take the place of those that have been killed off by antibiotics.

More information

The U.S. National Heart, Lung, and Blood Institute has more about cystic fibrosis.

-- Robert Preidt

SOURCE: University of Michigan, news release, March 26, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Girl Softball Players Suffering More Shoulder Injuries
2. Anthem Blue Crosss Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action
3. NIH Stem Cell Guidelines Should Be Modified, UCSF Team Reports
4. Rate Regulation for Health Insurance: Obama Administration Should Look to CAs Model Law Which Has Saved Drivers $62 Billion Since 1988
5. Virtually Everyone Should Get a Flu Shot: CDC
6. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
7. California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Young Men and Elderly Women at Biggest Risk for Shoulder Dislocations
11. Shoulder Dislocations a Sports Hazard
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Should Cystic Fibrosis Patients Get So Many Antibiotics? 
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, ... of Cisco Select certification and SMB specialization. Altura is now qualified to ... In earning the Select Certification, Altura fulfilled the training and exam requirements for ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of the Year, ... providing information destruction , recycling, and compliance services to businesses throughout ...
(Date:4/22/2017)... Freedom, PA (PRWEB) , ... April 22, 2017 ... ... healthcare experience to his role as Vice President of Sales and Business Development ... of key GPO/IDN business partner engagements, business development, and strategic planning for the ...
(Date:4/21/2017)... , ... April 21, 2017 , ... An April 10 ... a pair of ancient teeth, which reveal a great deal about prehistoric ice-age dental ... sharp stone may have been used to remove decayed dental matter, and that teeth ...
(Date:4/21/2017)... ... April 21, 2017 , ... The staff at Palm Beach Face is proud to announce ... the 2017 London Marathon. Set to take place on April 23rd, the London Marathon has ... Schwartz will run as part of team EMPOWER, raising money for the international charity, Smile ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: